purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation bmy earnings call period ending march image source motley fool bristol myers squibb bmy q earnings callapr etcontents prepared remark question answer call participant prepared remark operatorwelcome bristolmyers squibb firstquarter earnings conference call operator instruction please note today event recorded would like turn conference tim power vice president head investor relation please go aheadtim power vice president investor relation thank good morning everyone thanks joining u morning firstquarter earnings call joining morning prepared remark chris boerner board chair chief executive officer david elkins chief financial officer also participating today call adam lenkowsky chief commercialization officer samit hirawat chief medical officer head global drug development note posted slide bmscom use follow along chris david remark get started read forwardlooking statement call make statement company future plan prospect constitute forwardlooking statement actual result may differ materially indicated forwardlooking statement result various important factor including discussed sec filingsthese forwardlooking statement represent estimate today relied upon representing estimate future date specifically disclaim obligation update forwardlooking statement even estimate change also focus comment nongaap financial measure adjusted exclude certain specified item reconciliation certain nongaap financial measure comparable gaap measure available bmscom hand chris chris boerner chief executive officer thank tim good morning everyone q busy quarter u good start starting slide knowing active quarter wanted start telling think performance across four dimension first performance commercial portfolio good broadly line expectation even product impacted inventory gross net second made solid progress advancing pipeline third closed four import transaction strengthened longterm growth profile q fourth taking decisive action improve productivity taken together q performance broadly aligned internal expectation importantly change underlying business outlook provided february know included accounting impact recently closed transaction nongaap eps guidance let u turn slide detail start highlight commercial performance seen real strength across key brand including eliquis opdualag reblozyl yervoy breyanzi though bcma space remains competitive objective return abecma growth time karmma approval move larger patient population turning opdivo camzyos sotyktu important three brand demand grew revenue impacted factor inventory gross net today seeing inventory pattern opdivo camzyos normalizing sotyktu steadily building commercial script volume access continues improve year david give detail taken together commercial performance q line expectation set u year second made important progress advancing pipeline includes two important cell therapy approval initiation new registration trial important proofofconcept data opdualag lung cancer prespecified analysis phase q looking forward starting phase registrational trial versus standard care segment consisting nonsmall cell lung cancer patient slide important patient milvexian potential oral factor xia medicine afib ac trial continuing following recent dsmb review enrollment accelerating third closed four important deal quarter across four added asset capability expertise strengthen ability drive longterm growth exit team driving performance krazati rayzebio plant indiana operational process filing application supply clinical product ryz site systimmunes firstinclass bispecific adc advancing global clinical trial tumor including lung overtime breast cancer excited potential karxt karuna review slide team track focused two objective first launch preparation underway track karxt second executing robust clinical program important asset slide see significant unmet need schizophrenia highlight data recently presented karxt data demonstrated compelling longterm efficacy karxt associated significant improvement symptom schizophrenia across efficacy measure without evidence metabolic movement disorder side effect reinforces attractive profile medicine important advancement patient significant commercial opportunity company underpinning effort navigate decade enhanced focus driving operational productivity efficiency made notable progress already year let u go slide company level clearly identified brand program critical near latter half decade performance across organization initiated effort delayer streamline decisionmaking within rd optimizing portfolio focus internal effort higher roi program program compelling science significant commercial value therapeutic category bm positioned resourced win result action anticipate cost saving approximately billion end allow u reinvest high priority growth brand rd program heightened focus improving productivity efficiency strengthening company longterm growth profile snapshot busy start year clearly work year good start let close slide overall business outlook remains unchanged remain confident deliver top line growth year consistent communicated february underlying nongaap eps forecast also remained unchanged taking important action effectively manage decade management team focused ensuring disciplined execution required deliver year set u longer term want thank employee bm including new team member recent acquisition contribution commitment delivering patient let hand david daviddavid elkins chief financial officer thank chris good morning everyone chris highlighted good start year topline growth shown slide reminder unless otherwise stated comparison made period sale growth rate discussed underlying basis excludes impact foreign exchange building momentum coming last year executing plan drive growth portfolio delivered approximately sale increase first quarter compared prior year represents approximately total revenue growth broadbased growth brand recording significant increase quarter legacy portfolio also contributed overall sale growth quarter strong sale eliquis remains important cash flow generator company turning firstquarter performance key brand starting oncology slide slide see impact strategy broadening io franchise expanding new targeted solid tumor therapy global sale opdivo impacted inventory work timing order yous partially offset demand growth said past expect see growth modest pace opdualag standard care treatment firstline melanoma generated strong quarterly sale yous sale growth primarily driven strong market share encouraged future expansion potential opdualag adjuvant melanoma also plan develop firstline lung cancer along anticipated launch opdivo subcutaneous formulation next year extend io franchise well next date targeted solid tumor therapy expanded addition krazati completion mirati acquisition late january reported sale represent partial quarter pro forma basis krazati global sale q approximately million primarily yous recent conditional marketing approval european commission look forward bringing krazati patient toward end year augtyros firstquarter performance reflects positive early sale trend remain focused driving awareness penetration based upon potential bestinclass profile moving slide cardiovascular franchise eliquis remains marketleading oral anticoagulant worldwide q sale yous grew primarily due strong demand including increased market share internationally sale roughly line prior year camzyos generated strong sale quarter nearly tripling performance versus q last year yous sale driven demand growth including almost increase commercial dispenses since q sequentially yous sale camzyos impacted inventory dynamic approximately million grosstonet impact typical copay reset start new year expect momentum camzyos continue supported compelling realworld evidence patient presented earlier month acc let u turn slide discus hematology business legacy brand revlimid saw sale decline first quarter utilization free drug program normalized quarter continue anticipate variability revlimid sale quarter quarter based upon historic dispensing pattern specialty pharmacy anticipated increased volume yous generic starting march turning reblozyl growth quarter driven primarily strong yous launch broader command label firstline md international sale growth benefited new market launch look forward bringing reblozyl patient recent firstline approval eu japan cell therapy portfolio global breyanzi sale growth reflected strength clinical profile improved manufacturing capacity consistent previously communicated starting q expect breyanzi benefit recent new indication expanded manufacturing capacity abecma yous performance quarter impacted ongoing competitive pressure future demand benefit recent karmma approval expands addressable patient population internationally abecma demand growth offset unfavorable pricing pressure secure access moving immunology slide zeposia sale quarter primarily due demand new patient start multiple sclerosis sotyktu sale performed line expectation quarter delivered goal achieving roughly commercially paid prescription sale quarter reflected increased demand expanded commercial access addition expect add another large pbm later year expand access coverage approximately million life turning slide walk remainder pl comment nongaap basis expected gross margin decreased compared prior year primarily due product mix excluding acquired inprocess rd firstquarter operating expense increased mainly due impact recent acquisition higher cost support overall portfolio expect growth mitigated later year saving productivity initiative speak shortly income expense declined expected first quarter primarily due lower pd royalty rate financing cost associated recent transaction acquired inprocess rd quarter billion primarily due previously disclosed onetime charge billion karuna transaction million systimmune tax rate quarter impacted onetime nondeductible inprocess rd charge karuna impact acquired inprocess rd firstquarter earnings would taking account impact recent transaction including acquired inprocess rd reported earnings per share loss moving balance sheet capital allocation slide cash flow operation remained strong approximately billion generated quarter resulting approximately billion cash cash equivalent marketable debt security hand march strategic approach capital allocation remains unchanged committed dividend said previously plan utilize cash flow repay approximately billion debt next year remain financially disciplined around business development strengthen company longterm growth profile next let u turn slide discus productivity initiative chris described earlier taken action increase productivity efficiency focus effort asset highest potential roi likely drive longterm growth part process making deliberate choice prioritize asset greatest clinical benefit impact area high unmet need deliver value patient disproportionately invest higherreturn opportunity improves portfolio roi strengthens growth profile second half decade thoughtful process made decision discontinue externalize several clinical asset anticipate cost saving action approximately billion end thereby absorbing incremental opex expense recent deal cost saving come across organization include reduction direct clinical expense site rationalization elimination open role reduction headcount realize saving reinvest highest potential opportunity turning slide walk impact recently closed acquisition eps guidance see slide take previously stated nongaap eps guidance range february include previously stated impact deal dilution onetime impact acquired inprocess rd revised range continues reflect strong outlook business told february let u walk detail guidance slide starting revenue practice provide revenue guidance reported basis well underlying basis assumes currency remains consistent prior year continue expect total revenue increase low singledigit range report rate well excluding foreign exchange reflects confidence growing momentum growth portfolio including product opdivo reblozyl breyanzi camzyos sotyktu reminder sotatercept royalty included growth revenue line continue expect gross margin approximately saw last year see sequential dip q related sale mix excluding acquired inprocess rd continue expect total operating expense increase low singledigit range reflecting incremental cost associated recent acquisition partially offset realization internal saving productivity initiative mentioned earlier given timing deal closure expect come upper end guidance range expected stepup q remaining opex evenly spread across back half year remain aligned previous operating margin target least next year oie expect approximately million expense primarily reflecting debt financing cost karuna rayzebio tax rate affected onetime nondeductible expense karuna acquired process rd charge impacted nongaap net income excluding impact estimated underlying tax rate quarter result see fullyear underlying tax rate move qa let take minute review key highlight call today grew top line advanced pipeline executing productivity initiative expectation underlying strength business remains unchanged beginning year finally would like recognize bm employee around world unwavering hard work commitment continue make progress strengthening company longterm growth profile bringing truly transformational medicine patient turn call tim qatim power vice president investor relation thanks david go first question please question answer operatorabsolutely operator instruction first question come geoff meacham bank america please go aheadgeoff meacham bank america merrill lynch analyst good morning everyone thanks question one chris maybe david cost saving much would say legacy bristol either workforce facility versus optimizing integration recent deal guess trying get sense whether think optimization come guy focus new launch portfolio thank youchris boerner chief executive officer good morning geoff let david answer thatdavid elkins chief financial officer yes thanks jeff question majority saving come historical bm talked main driver billion saving really came three bucket first really looking portfolio obviously mirati karuna rayzebio really important portfolio bringing overall portfolio gave u opportunity look maximize roi totality portfolio well adjusting update new data competitiveness second thing really looked legacy bm become agile quicker decisionmaking streamline organization removing layer management decision quickly talked roughly affected employee result change lastly went thirdparty relationship continuing look efficiency thirdparty service provider last category lot activity also legacy bm vast majority saving coming inhouse existing operationstim power vice president investor relation thanks david go next question pleaseoperatorour next question come chris shibutani goldman sachs please go aheadchris shibutani goldman sachs analyst thank good morning obviously lot moving part operationally strategically think investor keen get sense thinking potentially trough level earnings think notion might visibility could begin see growth know vocabulary used exiting decade next help u thinking since clarity moving part thinking potential communicate kind timeline levelchris boerner chief executive officer ok chris take one think embedded question maybe two thing first thinking going guide around trough maybe second question think see trough timing respect first question look engaging investor topic last number month bit context given industry dynamic certainly believe company industry need judicious respect providing longterm guidance get asking question something going need continue engage investor strike right balance term think providing guidance topic little uncertainty know related question though impact ira eliquis price public remember going happen september time frame provide impact eliquis top line well eps term think timing trough based current plan start see impact said earlier year anticipate returning growth end decade obviously clearly focused accelerating timing pace growth back half decade going influence timing well thanks question christim power vice president investor relation right go next question pleaseoperatorour next question come chris schott jp morgan please go aheadchris schott jpmorgan chase company analyst great thanks much twoparter coming back restructuring guess first part redeployment saving going mostly focused rd side sga related term investment growth driver seems like element payer dynamic competitive launch impacting uptake new launch asset interested product see greatest potential improvement investment guess balance sga versus either rd dropping saving bottom line considering kind redeploy billionchris boerner chief executive officer thanks chris let say couple word turn david first part question adam come back end first david mentioned thought efficiency really thinking along three line need invest pipeline ensuring adequate investment growth product needing agile focused organization term think allocating redeployment opportunity would say generally speaking order majority going back rd david want startdavid elkins chief financial officer yes chris thanks question way think twothirds saving associated rd area third msa importantly really think acquisition done think mirati krazati particular really important development program firstline lung doublet well triplet think karuna adam talk see multiple indication billiondollar indication space talked schizophrenia adjuvant schizophrenia well moving alzheimers agitation psychosis significant investment make think ray ligand rayzebio see multiple md able come also finished manufacturing minneapolis going able supply clinical study significant investment three area well reprioritizing existing bm portfolio able increase roi portfolio importantly increased growth profile company second half decade lot work going surface order continue maximize value portfolio strengthen growth profile company adamadam lenkowsky chief commercialization officer yes chris thanks question making good progress across totality growth portfolio david shared saw strong yearonyear demand growth across majority growth product continue focused accelerating key brand said would continue drive growth portfolio product think important mention opdualag become new standard care firstline metastatic melanoma grew reblozyl continue deliver strong performance post firstline command approval grew well increased investment end last year behind product like sotyktu breyanzi camzyos camzyos continues demonstrate strong growth growth new patient added commercial drug quarter quarter breyanzi also increased investment much stronger supply position today last year increasingly recognized bestinclass cart david mentioned readying launch karxt september significant multibilliondollar opportunity would say product like abecma challenging u opportunity karmma approval work return back much growth time move larger patient population adding continue make good progress delivering strong commercial execution performancetim power vice president investor relation thanks adam go next question pleaseoperatorour next question come evan seigerman bmo please go aheadevan seigerman bmo capital market analyst hi guy thank much taking question kind followup talking talk cost saving reinvested mean going manage margin titrating reinvestment cost saving going deploy billion kind informed science potential growth followup mentioned going discontinue externalize several clinical asset commentary one thinking would greatchris boerner chief executive officer thanks evan david start samitdavid elkins chief financial officer yes thanks evan said prepared remark looking operating margin previously communicated range billion saving achieve end next year reinvested portfolio described earlier particularly acquisition also good progress like opdualag going continue clinical study well put together saying really strengthens roi growth profile business second half decade turn samit audit looking externalizesamit hirawat chief medical officer head global drug development yes thank david build david said pipeline perspective took thoughtful approach see rich pipeline asset going continuing first thing looked evolving science ongoing exploration clinical asset example look ctla pipeline developing set bar ipilimumab already high bar look data decided data going better ipilimumab continuing program decided continue similarly looked external internal data alpha program meet muster wanted look real return investment well patient going continue program second way looked science may really good data evolution really good really make sense company size continue program going ultimately growth driver perspective think data pretty good myelofibrosis really perspective meet threshold driver growth potential program going continuing course continue look dire either firstinclass bestinclass product profile perspective continue focus continue versus overall would say discontinued program time continuum throughout year continue look principle see else need take pipeline either externalize able develop furthertim power vice president investor relation thanks samit go next question please roccooperatorour next question come seamus fernandez guggenheim security please go aheadseamus fernandez guggenheim partner analyst great thanks question wanted check thought around ira impact associated approach particular might able provide u color progress process negotiation price fixing may come yous government second question hoping might comment help frame u opdivo opportunity lung cancer might gain incremental visibility going clinical trial hitting clinicaltrialsgov get information regard first actually see data potential subsetchris boerner chief executive officer thanks question seamus maybe start adam weigh little bit ira respect ongoing discussion cm going commenting said earlier outcome public september able provide insight point adam speak aspect ira samitadam lenkowsky chief commercialization officer yes thank chris seamus thanks question relates ira obviously multiple component negotiation also change part benefit design anticipate significant impact across portfolio across eliquis revlimid brand expect though substantial change part benefit next year since product impacted redesign carefully evaluating product individual dynamic see future monitoring closely understand impact example outofpocket cap shift happening system move cap cap would expect see patient ability fill medicine improve becomes lower pharmacy counter obviously need data provide additional detailssamit hirawat chief medical officer head global drug development thank adam thanks seamus question opdualag let u take step back understand planning try opdualag conducted study opdualag plus chemotherapy firstline nonsmall cell lung cancer first wanted define dose tested couple dos first part study second part study randomize patient receive opdualag plus chemotherapy versus nivolumab plus scheme therapy said wanted understand drug applicable patient going find differential activity subset patient said found subgroup patient drug activity good encourages u go phase trial looking forward presenting data second half year well initiating trial versus standard care second half year planning executing soon ready hearing addition opdualag course opportunity know already waiting data adjuvant melanoma trial looking forward data evolution toward back end year firstline hepatocelluar carcinoma welltim power vice president investor relation thanks much samit rocco could go next question pleaseoperatorour next question come terence flynn morgan stanley please go aheadterence flynn morgan stanley analyst great thanks taking question maybe twopart cart franchise david think mentioned something abecma exyous pricing dynamic change help boost access provide little bit detail oneoff specific country going breyanzi gilead talked recently moving yous secondary community hospital think expanding particularly secondline label indication something guy considering well feel pretty good current footprint breyanzi primary academic hospitalschris boerner chief executive officer thanks terence let adam take thoseadam lenkowsky chief commercialization officer relates breyanzi saw quarter able stabilize decline yous sale roughly flat versus last quarter referring internationally see strong demand growth expect continue demand growth offset negative price skew reimbursement mainly germany took place karmma give u opportunity different conversation customer data larger patient population return abecma growth time move much patient population breyanzi excited product q increased sale versus prior year anticipate robust growth year accelerated growth lbcl breyanzi increasingly recognized bestinclass cd also expect see expanded indication received approval yous cll additional approval anticipated next month follicular lymphoma mantle cell lymphoma going roughly double addressable market breyanzi also encouraged expanded manufacturing capacity much stronger position meet demand seeing outpatient use today breyanzi expect continue based differentiated safety profile taken together excited growth profile breyanzitim power vice president investor relation go next question pleaseoperatorour next question come tim anderson wolfe research please go aheadadam jolly wolfe research analyst adam tim wolfe research sotyktu give u updated market share metric thing like newtobrand share versus otezla oral category percent use firstline versus later line sort thing also detail free drug program might begin wind downchris boerner chief executive officer sure take adam thanks question continuing make progress sotyktu executing plan delivered quarter said would reaching approximately paid prescription shared january expect roughly double paid prescription q focused driving today remember also said would increase gross net due broader rebating needed secure improved access impacted sale q volume see offset throughout year talked improving access position aside win announced last year cv signet esi saw access improvement sotyktu added optum david mentioned expect announce additional improved formulary access including large pbm approximately million life remain focused securing zero step better access position need bridge becomes le le important basically look better access patient moved faster commercial product go directly specialty pharmacy far market share look highly competitive market look launch analog top funnel written prescription sotyktu performance ahead product like tremfya cosentyx time ago launch laser focused share growth versus otezla critical area focus becoming oral standard care market timetim power vice president investor relation thanks adam rocco could go next question pleaseoperatorour next question come dave risinger leerink partner please go aheaddavid risinger leerink partner analyst thanks much thanks thanks detailed perspective sharing hoping help income spec future including look astrazeneca income run rate anticipated step coming yearschris boerner chief executive officer thanks dave daviddavid elkins chief financial officer yes year big step pd rate thing impacting diabetes step next year well thing keep mind said prepared remark interest additional debt big change guidance provided year going million oie income million expense bulk related additional interest cost around billion interest rate slightly offset royalty incometim power vice president investor relation thanks david go next question pleaseoperatorand next question come mohit bansal well fargo please go aheadmohit bansal well fargo security analyst ok thank much question actually want probe trough guidance comment little bit seem like considering case talk little bit put take regarding timing guidance asking depends think trough mean might want provide still little bit uncertain regarding timing put take regarding timing eventually decide provide itchris boerner chief executive officer yes maybe start david chime additional anything else would like provide think way thinking trough guidance something engaged investor last number month think way would think first foremost probably underlying question guidance right impact ira eliquis said earlier position september price eliquis coming ira process known public point talk price impact eliquis top line well eps term thinking timing trough said back beginning year see impact starting plan growing end decade david anything else would adddavid elkins chief financial officer think covered christim power vice president investor relation thanks chris could go next question please roccooperatorour next question carter gould barclays please go aheadcarter gould barclays analyst good morning thanks taking question color today wanted dig camzyos second data acc sort current rate one seemed positive think rem registry data potential potentially get rem modified road reading data level confidence anything front want message guess along line well believe housekeeping hear million inventory impact quarter know something called slide sure quantified help would great toochris boerner chief executive officer yes thanks carter maybe samit start adamsamit hirawat chief medical officer head global drug development yes thank carter question camzyos remain obviously confident overall profile camzyos transformational therapy patient mentioned data acc clearly showed patient treated real world transformational outcome safety perspective patient treated milligram dose overall outcome remain really really positive well impact ejection fraction minimal best certainly give u opportunity collate data find conversation continuing fda appropriate time remember also got nonobstructive hypothetic cardiomyopathy study reading early next year provide another opportunity u also engage deeper conversation rem program whole bring therapy patient well decrease burden patient let pas adam comment moreadam lenkowsky chief commercialization officer yes thanks question pleased camzyos performance quarter saw nice acceleration new patient start saw increase patient added commercial dispense offset mentioned approximately million inventory work q q saw gross net impact well copay restart happened beginning year see camzyos consistent positive feedback physician patient positive also making good progress launch internationally work secure reimbursement seeing good momentum camzyos feel good performance important product end year suretim power vice president investor relation great let u go next questionoperatorand next question come steve scala td cowen please go aheadsteve scala td cowen analyst thank much different version earlier question number potential obstacle bristol future eliquis ira price patent exploration opdivo patent exploration patent expiration etc based reply earlier question sound like bristol view ira price eliquis single biggest obstacle profit next decade conclusion would like u draw second question noted revlimid free drug lower q confirm consistent prior revlimid guidance reason lower fewer patient requesting free drug bristol changed termschris boerner chief executive officer steve start ask last part question highlighted issue around eliquis price negotiation important consideration midterm think sort transition period going talked middle decade greater insight impact later year able provide estimate impact top line eps get back half decade time would say though step back mean clearly articulated importance eliquis discussed past number loes faced course decade think important note well talked lot importance growth portfolio saw nice doubledigit growth portfolio quarter actually overall business comprised portfolio product remember diversified portfolio asset across therapeutic area feel good potential portfolio going end year catalyst growth back half decade saw nice progress pipeline course quarter think important recognize ira impact middle decade feel good able compensate young attractive growth profile coming growth portfolio pipeline daviddavid elkins chief financial officer steve question around revlimid couple comment make one said free drug program come normal level change program throughout last year level came start year remember every calendar year start back traditional level relation comment thing relates revlimid said change guidance year previously said billion billion step year next year year remember exited last year billion billion billion best view year step next year loe revlimid basically end next year chris talked get insight happening eliquis ira perspective price becomes public september recall loe eliquis lastly thing would say loe perspective relates opdivo loe december loe would start three thing would say think franchise one looking forward launching subcutaneous formulation early next year believe help franchise continue next decade think heard samit talk opdualag combination really excited number one performance standard care firstline melanoma also data seeing lung really excited continuing program phase bringing also tumor type opdualag come think franchise multiple avenue franchise continue next decadechris boerner chief executive officer adding one thing steve around revlimid seen volatility generic dispensing quarter including generic supply shortage revlimid legacy portfolio continues strong source cash flow organizationtim power vice president investor relation great let u go next question pleaseoperatorand next question today come trung nguyen ubs please go aheadtrung nguyen ubs analyst hi guy trung nguyen ubs two ok one costsaving program billion split year change opex guide think noted saving absorbed deal main year see cost realized abecma karmma label noted going important growth quickly start see helping realistic see inflection immediatelychris boerner chief executive officer thanks question david adamdavid elkins chief financial officer yes vast majority saving come year think action taking whether position portfolio action made action immediately thirdparty spend receive annualize fully next year really difference safe say action taking done quarteradam lenkowsky chief commercialization officer yes trung relates abecma certainly pleased regulatory approval karmma triple classexposed setting yous europe japan remain competitive space multiple product modality available focus educating physician karmma data abecmas differentiated predictable safety profile well manufacturing reliability abecma also focused expanding site footprint yous around globe making abecma available patient believe place multiple asset market objective return abecma growth time move larger patient populationtim power vice president investor relation let u go next question pleaseoperatorour next question come matthew phipps william blair please go aheadmatt phipps william blair company analyst hi thanks taking question adam wondering comment path grow opdualag melanoma outside united state additional data needed maybe samit krystal suppose give u tidbit trend overall survival point know study ongoing maybe confidence data set stand today able support full approvaladam lenkowsky chief commercialization officer yes start thanks question first would say pleased continued progress opdualag become standard care united state firstline metastatic melanoma saw growth versus prior year market share yous still room grow penetrating still around monotherapy use exciting also starting launch internationally market like australia canada brazil well several european market still opportunity launch germany working negotiation hopeful opportunity launch sometime back end year next year additionally spoken earlier pleased proofofconcept study lag top pdl chemo firstline lung cancer add coupled opportunity lung melanoma opdualag truly potential meaningfully extend io franchise well next decadesamit hirawat chief medical officer head global drug development thank question think krystal trial remember study progressionfree survival see data presented asco overall survival data remains immature time able comment specific really excited confirmation single arm previously done randomized study heretim power vice president investor relation let u go next question pleaseoperatorour next question come olivia brayer cantor fitzgeraldolivia brayer cantor fitzgerald analyst hey good morning guy thank question commercial rollout strategy look like karxt look past september pdufa thought around medicaid negotiation think start see meaningful growth franchise whether next year chris boerner chief executive officer adamadam lenkowsky chief commercialization officer yes thanks question excited opportunity launch karxt later year important drug significant commercial potential talked karxt first innovative therapy schizophrenia approved decade shared karxt offer like prexileg efficacy without significant adverse event plagued weight gain lipidemia eps know compelling physician rapidly preparing launch plan going well ready launch summer well advance pdufa date focused prelaunch effort made good progress preparing launch karuna made good progress sourcing experienced commercial organization field medical access team already begun meaningful conversation thought leader payer prelaunch effort today focused driving awareness new mechanism currently building large neuroscience field sale organization fact increased investment across multiple front maximize opportunity also need ensure physician positive first experience building customer model make sure optimal physician caregiver patient support alluded know achieving rapid access important largely medicaid medicare opportunity around access team already today leverage large access organization ensure rapid access patient team already meeting state medicaid director feedback product profile positive half state medicaid program either step edits single step edit goal improve quality access one step edit know going take time confident ability achieve quality access product given september pdufa timeline obtain broad medicaid coverage effectively see launch excited potential karxt plan make big product bristolmyers squibbtim power vice president investor relation thanks adam starting run little short time maybe take two three go next oneoperatorour next question come james shin deutsche bank please go aheadjames shin deutsche bank analyst hey good morning guy thanks taking question question opdualag phase frontline multiple cell lung full data set readout second half share seen different comparable lag nonsmall cell data set tacdsamit hirawat chief medical officer head global drug development certainly take question look obviously comment others seen know seen six patient worth data hard compare six patient worth data patient treated opdualag plus chemotherapy firstline setting seen overall review data set looking various endpoint looked well biomarkers looked file remain confident profile drug take forward phase tim power vice president investor relation ok let u go next one pleaseoperatorour next question come kripa devarakonda truist security please go aheadkripa devarakonda truist security analyst hi guy thank much taking question color call question acquisition rayzebio got enablement seeing getting competitive wanted see urgency strategy build radiopharma pipeline also see detail priority also regarding actinium production going livechris boerner chief executive officer well let start ask samit adam speak let high level though say continue incredibly excited radiopharmaceutical platform one fastestgrowing platform solid tumor oncology believe bestinclass asset acquired rayze integration team gone well continue excited happy bringing online facility indianapolis term u getting asset incredible enthusiasm integration gone well samit maybe adam speak detailssamit hirawat chief medical officer head global drug development yes thank question rayze chris mentioned platform absolutely exciting encouraging data seen emerging first program already phase sstr directed radioligand therapy phase program right enrolling gap net indication well small cell lung cancer phase study ongoing looking see couple indication added designing trial speak conduct hold huge amount promise specificity directed radiation tumor thereafter looking forward additional ind filing later year might able start actually specific tumordirected indication within hcc back half year thereafter looking ind generation coming platform go forward within indianapolis manufacturing facility running looking forward supplying actinium part well drug product toward back half back end early part next year certainly help term continuing supply taking forward learning lesson front runner lesson helpful go commercial stage couple yearschris boerner chief executive officer adam anything addadam lenkowsky chief commercialization officer yes add thing rayzebio important strategic acquisition believe continue diversify oncology portfolio chris mentioned see modality going continue grow time competitive space liked rayzebio going ind engine lead program ryz already phase development heard earlier gap net opportunity small cell lung cancer breast cancer potentially many tumor type tremendously complementary existing portfoliotim power vice president investor relation maybe go last question mind roccooperatorour final question come akash tewari jefferies please go aheadunknown speaker morning thanks taking question avi akash two quick question first one followup karxt think patient drug develop cardio dyskinesia help position karxt schilphrenia market second question cart think cart autoimmune attractive cd bispecifics also would consider approach require depletionchris boerner chief executive officer samitsamit hirawat chief medical officer head global drug development sure thank first great profile karxt think adam spoken earlier safety profile perspective data recently presented also sur conference see toxicity seen atypical target dyskinesia movement disorder well many element spoken repeat confident profile looking forward bring patient schizophrenia david said earlier indication well adsychosis agitation bipolar disorder others exploring cart side certainly advantage single infusion leading good outcome patient especially starting sle refractory setting patient multiple treatment ongoing organ dysfunction factor patient advantage single infusion cause tremendous transformational outcome patient know program quite large also looking multiple sclerosis well systemic sclerosis well idiopathic fibrosis program enroll patient generate data hoping able present data sle year certainly future approach might include nonlymphodepletion therapy ready right nowchris boerner chief executive officer thanks samit maybe close saying first thank joining call today know busy day maybe leave thing first good start performance quarter reflects execution action taken strengthen company longterm growth profile business remains unchanged beginning year course look forward sharing continued progress future call close call always team available answer question following today discussion hope good dayoperatoroperator signoff duration minutescall participantstim power vice president investor relationschris boerner chief executive officerdavid elkins chief financial officergeoff meacham bank america merrill lynch analystchris shibutani goldman sachs analystchris schott jpmorgan chase company analystadam lenkowsky chief commercialization officerevan seigerman bmo capital market analystsamit hirawat chief medical officer head global drug developmentseamus fernandez guggenheim partner analystterence flynn morgan stanley analystadam jolly wolfe research analystdavid risinger leerink partner analystmohit bansal well fargo security analystcarter gould barclays analyststeve scala td cowen analysttrung nguyen ubs analystmatt phipps william blair company analystolivia brayer cantor fitzgerald analystjames shin deutsche bank analystkripa devarakonda truist security analystunknown speaker bmy analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends bristol myers squibb motley fool disclosure policy